Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC

Exelixis, Inc. (EXEL) entered into a clinical development collaboration agreement with pharma giant Merck (MRK) to advance the development of its pipeline candidate, zanzalintinib. Zanzalintinib, an investigational tyrosine kinase inhibitor (TKI), inhibits multiple cancer-related pathways that play a key role in resistance to multiple therapies, including immune checkpoint inhibitors. Shares of Exelixis have risen 9.4% year to date compared with the industry's growth of 6.3%. Image Source: Zacks Investment ...